<?xml version="1.0" encoding="UTF-8"?>
<p id="Par46">Three cohort studies [
 <xref ref-type="bibr" rid="CR44">44</xref>, 
 <xref ref-type="bibr" rid="CR45">45</xref>, 
 <xref ref-type="bibr" rid="CR48">48</xref>] and one case control studies [
 <xref ref-type="bibr" rid="CR38">38</xref>] were included to compare mild/moderate versus severe/critical COVID-19 stages in COVID-19/TB co-infected patients. The pooled result revealed that the COVID-19/TB group was at high risk of developing severe/critical COVID-19 compared to the COVID-19 group OR 4.50 (95%CI 1.12–18.10, 
 <italic>P</italic> = 0.03). The test of heterogeneity was not statistically significant 
 <italic>P</italic> = 0.16, 
 <italic>I</italic>
 <sup>2</sup> = 42% (Fig. 
 <xref rid="Fig4" ref-type="fig">4</xref>). 
</p>
